BioSpace News Archive

Hemogenyx Pharmaceuticals plc announces that its wholly owned subsidiary Immugenyx, LLC (“Immugenyx”) has entered into a collaboration agreement with Orgenesis, Inc.

Data Show Vectra Test Is Correlated with Treatment Response

MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Janssen Research & Development, LLC, has announced new long-term data from the open-label-period of the phase 3 VOYAGE 1 clinical trial demonstrating stably maintained rates of skin clearance with Tremfya(R) treatment at week 52 (1 year) and week 156 (3 years) among adult patients with moderate to severe plaque psoriasis.

Data presented indicate that TSR-042 (anti-PD-1 antibody) is well tolerated and has robust activity in patients with MSI-H endometrial cancer

Adaptimmune Therapeutics plc presented initial data from the first two cohorts of its ongoing studies with its MAGE-A10 and MAGE-A4 SPEAR T-cells in two poster presentations earlier today at the European Society for Medical Oncology (ESMO) Congress in Munich, Germany.

What is AbbVie thinking? That’s the question of many investors, analysts and industry watchers as the Chicago-based AbbVie decided to buy up researcher partner Galapagos’ cystic fibrosis portfolio instead of walking away.

Medtronic plc announced today that its co-founder, Earl E. Bakken, passed away peacefully on October 21, 2018 at his home on Kiholo Bay on the Big Island of Hawaii. He was 94 years old.

As part of a plan to lower prescription drug prices for millions of Americans, President Donald Trump is set to announce a sweeping plan to overhaul how Medicare pays for medication.

After releasing positive topline data from the Phase II study of BAN2401 as a potential treatment for Alzheimer’s disease in July, some of the numbers did not hold up. This morning Biogen and its developmental partner Eisai attempted to provide an update on the information to show that the anti-amyloid plaque treatment still has some life.

Recipharm today announces that it will continue the manufacturing operations at its facility in Höganäs, Sweden, operations that earlier were set towards being discontinued.